Medifast Earnings Disappoint as Revenue Plunges Amid Economic Uncertainty

Medifast, a wellness company, is preparing to report its Q2 2025 earnings on Monday afternoon. The company faced a mixed Q1 2025, missing analysts' revenue expectations by 0.6% but beating their EPS estimates.

Looking ahead to Q2 2025, analysts are expecting Medifast's revenue to decline 39.6% year-over-year to $101.8 million, an improvement from the 43.1% decrease recorded in the same quarter last year. The company is also expected to report an adjusted loss of $0.19 per share.

Analysts covering Medifast have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. However, the company has missed Wall Street's revenue estimates twice over the last two years.

The performance of Medifast's peers in the consumer staples segment provides some insight into what to expect. USANA and Nature's Sunshine, two other companies in the sector, have already reported their Q2 2025 results, with both delivering year-over-year revenue growth and beating analysts' expectations.

Despite the solid performance of some consumer staples stocks, the group has generally underperformed, with share prices down 2.4% on average over the last month. Medifast is down 6.1% during the same time and is heading into earnings with an average analyst price target of $15, compared to the current share price of $13.75.